gilead report good earn biktarvi look multi-billion product
model annual revenu antivir busi appear rel stabl
howev seemingli stabil result estim compound-annual-growth-rate
excit therefor view broader issu
larg base revenu requir pipelin signific magnitud achiev attract
growth current compani bet three key franchis yescarta/car-
filgotinib/or jak nash none terribl high level
confid per quarterli updat lower peak yescarta sale
estim push filgotinib launch back year time still uncertain
consequ model chang lead us decreas price target
downgrad neutral given limit upsid level
biktarvi perform led near-term increas number peak sale
remain larg biktarvi beat report quarterli sale
q/q led us increas ramp launch next two year
meaning chang peak sale number still product
approach annual sale three year street
antivir franchis next year primari concern compani abil
transit truvada franchis estim hiv sale year
descovi final per compani magnitud uncertain anoth step
hcv price like occur next year
yescarta/cellular therapi estim decreas yescarta sale continu fall short
expect q/q increas yescarta sale
third full quarter launch inspir perform consist
recent kol feedback car-t gener note high level frustrat
price product failur relaps rate result lower
yescarta/cellular therapi sale estim
filgotinib launch push back latest filgotinib result good
manag note male testicular tox studi gate item file time
complet uncertain given difficulti enrol patient consid updat
enrol complet januari push launch back end
would make oral jak market could still aggress
model nash await phase result
believ signific risk given tough fibrosi primari endpoint recent
increas competition/expect even posit seriou concern
size market opportun given diagnosi current requir biopsi
dcf includ
antivir franchis grow
beyond continu success yescarta
launch eventu success filgotinib
debt total capit
commerci risk antivir franchis yescarta clinic risk filgotinib
gilead world leader antiviral/anti-inflammatori medicin cellular therapi
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
launch us eu
dlbcl pmbcl tfl on-going
dlbcl pmbcl tfl
nash psc
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
total antivir product sale
total antivir product sale
total antivir product sale
total product sale
total product sale
total gilead revenu
total gilead revenu
good sold
revenu
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
total hiv product sale
address broader patient group boost integras interact statin
total hiv product sale
total hiv product sale
total hiv product sale
total hiv product sale
total hiv product sale
total antivir product sale
total antivir product sale
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
hcv product sale
hcv product sale
total antivir revenu
total gilead revenu
total product sale
total product sale
total gilead revenu
total gilead revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
total hiv product sale
total hiv product sale
total hiv product sale
total hiv product sale
total hiv product sale
total hiv product sale
total antivir product sale
total antivir product sale
hcv product sale
hcv product sale
total antivir product sale
total product sale
total product sale
total product sale
total product sale
total gilead revenu
good sold
revenu
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
